FDA Advisers Vote In Favor Of Recommending New Covid Vaccine Target JN.1 Lineage For 2024-25 Campaign
Portfolio Pulse from Benzinga Newsdesk
FDA advisers have voted in favor of recommending a new Covid vaccine targeting the JN.1 lineage for the 2024-25 campaign.
June 05, 2024 | 6:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca may benefit from the FDA's recommendation of a new Covid vaccine targeting the JN.1 lineage for the 2024-25 campaign.
As a major player in the Covid vaccine market, AstraZeneca stands to benefit from new vaccine recommendations, potentially boosting sales and market share.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
BioNTech may experience positive effects from the FDA's recommendation of a new Covid vaccine targeting the JN.1 lineage for the 2024-25 campaign.
BioNTech, as a key player in the Covid vaccine market, could see increased demand and revenue from the new vaccine recommendation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Johnson & Johnson may benefit from the FDA's recommendation of a new Covid vaccine targeting the JN.1 lineage for the 2024-25 campaign.
Johnson & Johnson, being a significant player in the Covid vaccine market, stands to benefit from new vaccine recommendations, potentially boosting sales and market share.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Moderna may experience positive effects from the FDA's recommendation of a new Covid vaccine targeting the JN.1 lineage for the 2024-25 campaign.
Moderna, as a key player in the Covid vaccine market, could see increased demand and revenue from the new vaccine recommendation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Novavax may benefit from the FDA's recommendation of a new Covid vaccine targeting the JN.1 lineage for the 2024-25 campaign.
Novavax, being a significant player in the Covid vaccine market, stands to benefit from new vaccine recommendations, potentially boosting sales and market share.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Pfizer may experience positive effects from the FDA's recommendation of a new Covid vaccine targeting the JN.1 lineage for the 2024-25 campaign.
Pfizer, as a key player in the Covid vaccine market, could see increased demand and revenue from the new vaccine recommendation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50